Old Web
English
Sign In
Acemap
>
authorDetail
>
Keavy A. Gaines
Keavy A. Gaines
Merck & Co.
Internal medicine
Osteoporosis
Medicine
Endocrinology
Tolerability
4
Papers
241
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone Density and Turnover in Postmenopausal Women with Osteoporosis
2006
Clinical Drug Investigation
David M. Reid
David J. Hosking
David L. Kendler
Maria Luisa Brandi
John D. Wark
Georges Weryha
João Francisco Marques-Neto
Keavy A. Gaines
Nadia Verbruggen
Mary E. Melton
Show All
Source
Cite
Save
Citations (27)
Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study
2004
Current Medical Research and Opinion
John A. Eisman
R. Rizzoli
J. Roman-Ivorra
S. Lipschitz
Nadia Verbruggen
Keavy A. Gaines
Mary E. Melton
Show All
Source
Cite
Save
Citations (34)
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate
2004
Maturitas
David L. Kendler
Annie Wai-Chee Kung
Ghada El Hajj-Fuleihan
José Gerardo González-González
Keavy A. Gaines
Nadia Verbruggen
Mary E. Melton
Show All
Source
Cite
Save
Citations (98)
ALENDRONATE PRODUCES GREATER EFFECTS THAN RALOXIFENE ON BONE DENSITY AND BONE TURNOVER IN POSTMENOPAUSAL WOMEN WITH LOW BONE DENSITY: RESULTS OF EFFECT (EFFICACY OF FOSAMAX VERSUS EVISTA COMPARISON TRIAL) INTERNATIONAL
2004
Journal of Internal Medicine
Philip N. Sambrook
Piet Geusens
C. Ribot
Ja Solimano
J. Ferrer-Barriendos
Keavy A. Gaines
Nadia Verbruggen
Mary E. Melton
Show All
Source
Cite
Save
Citations (82)
1